Providence Ventures was founded in 2014 and manages $300 million of venture capital in two funds.
The company is affiliated with Providence, a 51-hospital health system that has more than 800 clinics in five states. The fund makes direct investments in healthcare companies with the goal of improving outcomes and convenience while lowering costs.
BALTIMORE, July 10, 2020 /PRNewswire/ — Johns Hopkins University filed suit in federal court Friday in an effort to stop a Trump administration rule change that would severely impact nearly 5,000 international students at the university. The decision to abruptly rescind accommodations for online learning during the COVID pandemic is unlawful and fails to consider the many complexities of meeting our educational mission while also protecting the health of our community.
The suit was filed in the Federal District Court for Washington, D.C., which has significant expertise in handling challenges against unlawful action by the federal government, and it joins other litigation related to the new rule filed by Harvard, MIT and the University of California. Johns Hopkins’ plans for a hybrid, online/in-person model for some of its divisions presents the broadest array of issues for the courts to consider.
(CNN) – If the year 2020 is good for anything, it’s the lesson that during a crisis, anyone who builds a better mousetrap will find the world beating a path to his door.
A humble team at Johns Hopkins University in Maryland reminded the world of late poet Ralph Waldo Emerson’s phrase when they created a real time tracking map of coronavirus cases and deaths.
And the world came to their door. They report that the site, plus downloads of its data, hosts three to five billion interactions daily. By their measurement, interactions include uses of the public dashboard and requests from a separate website for the underlying data used by news outlets and others who design their own maps and graphics.
Image: Civil engineering professor Lauren Gardner, of the Center for Systems Science and Engineering at Johns Hopkins University, is the lead behind the dashboard project.
NEW YORK and GAITHERSBURG, Md. and NEW ORLEANS and LAFAYETTE, La., July 08, 2020 (GLOBE NEWSWIRE) — The Mount Sinai Health System, Emergent BioSolutions (NYSE: EBS), and ImmunoTek Bio Centers today announced that they will collaborate to develop, manufacture, and conduct clinical trials to evaluate Emergent’s COVID-19 hyperimmune globulin product, COVID-HIG, including a post-exposure prophylaxis (PEP) study on health care providers at high risk of COVID-19 infection and other high-risk populations, with $34.6 million in funding from the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND).
VIENNA, AUSTRIA and GAITHERSBURG, MD, July 8, 2020 APEIRON Biologics AG (“APEIRON”), a private biotechnology company specializing in the discovery, development and commercialization of novel immunotherapies for cancer and respiratory diseases, and MaxCyte, Inc., a global cell-based therapies and life sciences company, today announces the signing of a clinical and commercial licensing agreement.
APEIRON Biologics will obtain non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for the advancement of APN401, a siRNA-based cell therapy currently in clinical development for various solid tumors. In return, MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to other licensing fees.
GSK and Medicago today announced a collaboration to develop and evaluate a COVID-19 candidate vaccine combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system. CoVLPs mimic the structure of the virus responsible for COVID-19 disease, allowing them to be recognised by the immune system. Use of an adjuvant can be of particular importance in a pandemic situation as it may boost the immune response and reduce the amount of antigen required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people.
BHI’s own Rich Bendis will Moderate.
Join us for a lively discussion between our region’s top innovators and connectors to hear about their efforts to help grow the innovation ecosystem and the pipeline of successful startups across the BioHealth Capital Region.
On this webinar, you will learn how you can take advantage of the many resources available throughout the region that will help your company go to market AND increase the opportunity to find success in the process.
Fueling an Innovation Ecosystem for Startups to Thrive
Click here for more information and to register.
BHI’s own Rich Bendis will Moderate.
Join us for a lively discussion between our region’s top innovators and connectors to hear about their efforts to help grow the innovation ecosystem and the pipeline of successful startups across the BioHealth Capital Region.
On this webinar, you will learn how you can take advantage of the many resources available throughout the region that will help your company go to market AND increase the opportunity to find success in the process.
Fueling an Innovation Ecosystem for Startups to Thrive
Click here for more information and to register.
Four more US biotechs filed to go pub lic Fri day as yet more com pa nies clam ber to get through a yawn ing IPO win dow and on to a mar ket that’s sig naled its will ing ness to re ward near ly any new drug mak er.
The new en trants are led by ALX On col o gy and the bi o log i cal an a lyt ics biotech Berke ley Lights, each of whom filed to raise $100 mil lion. The au toim mune com pa ny Pan dion Ther a peu tics al so filed for $75 mil lion, and Kiromic Bio phar ma, a tiny im muno-on col o gy start up based in San An to nio, filed for $25 mil lion.
Paul Rothman, MD, CEO of Baltimore-based Johns Hopkins Medicine and dean of the medical faculty at Johns Hopkins University, discussed the health system’s COVID-19 data platform and the potential for artificial intelligence to make a difference in how health systems approach treatment in the future in an interview with The Media Line.
Since the pandemic began, Johns Hopkins has gathered COVID-19 data and reported it on a public dashboard for cases and deaths in the U.S. and across the world. Dr. Rothman said the health system is using artificial intelligence and machine learning in its platform and aims to collaborate with others to incorporate data in the future.
